Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$10.82B
Positions
136
New
18
Increased
27
Decreased
9
Sold Out
10
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $10.82B across 136 positions in their Q3 2015 SEC 13F filing (period ending 2015-09-30). The top 10 positions account for 77.5% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | INCYIncyte Corporation | $2.15B | 19.85% | +31.0% |
| 2 | SGENEURSeattle Genetics, Inc. | $1.39B | 12.84% | +16.7% |
| 3 | ALXNAlexion Pharmaceuticals, Inc. | $1.02B | 9.45% | - |
| 4 | ABBVAbbVie Inc. | $782.06M | 7.23% | - |
| 5 | ACADACADIA Pharmaceuticals Inc. | $677.32M | 6.26% | - |
| 6 | Incyte Corporation Notes 1.25% 11/15/2020 144A | $598.70M | 5.53% | - |
| 7 | Incyte Corporation Notes 0.375% 11/15/2018 144A | $559.64M | 5.17% | - |
| 8 | Anacor Pharmaceuticals, Inc. | $486.78M | 4.50% | +14.1% |
| 9 | BMRNBioMarin Pharmaceutical Inc. | $429.32M | 3.97% | -0.5% |
| 10 | GHDXGenomic Health Inc. | $289.01M | 2.67% | +0.0% |
| Stock | Value | Shares |
|---|---|---|
| CLVS 2.5 09/15/21Clovis Oncology Inc. 2.5% 9/15/2021 | $215.31M | 129,300,000 |
| Medivation, Inc. | $28.04M | 659,752 |
| ZGNXEURZogenix, Inc. | $24.28M | 1,798,365 |
| EXEL 4.25 08/15/19Exelisis, Inc. Notes 4.25% 8/15/2019 | $23.99M | 20,000,000 |
| AEGR 2 08/15/19Aegerion Pharmaceuticals, Inc. Notes 2.0% 8/15/2019 | $19.87M | 26,517,000 |
| AKTXAkari Therapeutics PLC ADR | $9.50M | 395,882 |
| GBTUSDGlobal Blood Therapeutics, Inc. | $8.43M | 200,000 |
| AIMTAimmune Therapeutics, Inc. | $6.33M | 250,000 |
| Endocyte, Inc. | $6.21M | 1,356,552 |
| TRVNTrevena, Inc. | $4.66M | 450,000 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.